Does ART prevent HIV transmission among MSM? by Muessig, Kathryn E. et al.
Does ART prevent HIV transmission among MSM?
Kathryn E. Muessiga, M. Kumi Smithb, Kimberly A. Powersa,b, Ying-Ru Loc, David N.
Burnsd, Andrew E. Gruliche, Andrew N. Phillipsf, and Myron S. Cohena,b,g
aDepartment of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA
bDepartment of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA
cDepartment of HIV/AIDS, World Health Organization, Geneva, Switzerland dDivision of AIDS,
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda,
Maryland, USA eKirby Institute (formerly the National Centre in HIV Epidemiology and Clinical
Research), University of New South Wales, Sydney, Australia fDepartment of Infection and
Population Health, University College London, London, UK gDepartment of Microbiology and
Immunology, University of North Carolina, Chapel Hill, North Carolina, USA
Keywords
HIV; sexually transmitted diseases; Highly Active Antiretroviral Therapy; men who have sex with
men; MSM; treatment as prevention
One randomized controlled trial [1] and numerous observational studies [2–6] provide
strong evidence that antiretroviral therapy (ART) can reduce or prevent the sexual
transmission of HIV-1 within serodiscordant heterosexual couples. A key question remains:
does ART reduce HIV transmission among men who have sex with men (MSM), where the
primary mode of transmission is via condomless anal intercourse? New WHO guidelines for
earlier initiation of ART among serodiscordant couples were released in April 2012 [7] and
some countries, such as China, have already embraced treatment as prevention (TasP) for
heterosexual couples. In the process of reevaluating current ART guidelines, we anticipate
that for some countries, the issue of whether to recommend TasP for MSM will be under
debate. The evidence supporting TasP for MSM is promising, but major gaps in our
knowledge remain. To identify priority areas for research, in this paper we synthesize
evidence of (a) the biological plausibility that virally suppressive ART reduces HIV
infectiousness via anal intercourse and (b) epidemiologic evidence of whether ART has
played a role in attenuating HIV incidence among MSM.
Some biological and epidemiological evidence suggests that ART for preventing
transmission via anal intercourse may have more limited efficacy than via vaginal
intercourse. Without ART, the probability of HIV transmission is estimated as 1 infection
for every 20 to 300 acts of condomless anal intercourse, as compared to 1 in 200 to 1 in
2,000 for penile-vaginal exposure [8–13]. Additionally, a higher median number of HIV
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variants are transmitted in MSM couples as compared to heterosexual couples [14–16]
potentially posing greater challenges for drug resistance [17].
The pharmacology of antiretroviral (ARV) agents also differs between the urogenital tract
(vaginal intercourse) and the gastrointestinal (GI) tract (anal intercourse). ARVs can reduce–
—but not eliminate–—the amount of HIV recovered from the genital tract [18–20] and GI
tract [21–23]. Higher levels of HIV DNA and RNA have been found in the GI tract
(duodenum, ileum, ascending colon, and rectum) as compared to the blood [24,25] and
semen [23] irrespective of ART use, although these levels may be positively correlated
[21,26,27]. Some ARVs such as tenofovir, tenofovir diphosphate, and maraviroc have been
shown to penetrate rectal tissue with greater efficiency than blood or seminal plasma [28,29]
but the durability of this penetration and required levels for prevention are not yet
established. Furthermore, paired blood and rectal biopsy samples tested for resistance to
ARVs have shown different mutation profiles in the virus recovered from each site [30].
This would suggest that replication can persist in the rectum even if a patient appears
otherwise virally suppressed. While the results of HPTN 052 demonstrated the capacity of
ARVs to markedly reduce the risk of penile-vaginal transmission despite similar biological
and pharmacokinetic uncertainties, we cannot be certain that this will be the case for anal
intercourse given the much higher transmission probability in the absence of ART.
In addition, we do not know the extent to which sexual risk behaviors might offset the
potential prevention benefits of ART. Increases in bacterial sexually transmitted infections
(STIs) are compelling evidence of ongoing high-risk behaviors among MSM [31–35] and
these co-infections amplify HIV transmission [36–41]. Globally, there is evidence of
increases in STIs among MSM including rectal gonorrhea [31,33,34,42], urethral gonorrhea
[43], and syphilis [33,34,44–46]. Other behaviors such as serosorting (limiting sexual
partners to those thought to be the same HIV serostatus) [47] and rectal douching [48] also
alter the risk of HIV transmission among MSM.
We do not know the extent to which sexual risk behaviors among MSM are changing due to
the increasing availability of ART. Positive beliefs about the protective ability of ART
(treatment optimism) [49–51] and being on ART itself [51–54], irrespective of actual viral
suppression, have been associated with increased condomless anal intercourse. A meta-
analytic review of studies published between 1996 and 2003 found a non-significant
association between taking ART and increased condomless anal intercourse among MSM
(OR 1.38, 95% CI, 0.62–3.07); however, the belief that being on ART protects against
transmission was associated with an almost two-fold increase in condomless anal intercourse
(OR 1.84, 95% CI, 1.53–2.20) [55]. The number of studies on these impacts of ART on
behavior has more than doubled since this review and an updated meta-analysis has been
commissioned by the WHO with results anticipated in 2012. Changes in transmission risk
behaviors are also being assessed as a secondary outcome in the randomized controlled
START trial (Strategic Timing of Antiretroviral Treatment), a study among treatment naïve
HIV-positive persons recruited from over 200 sites worldwide comparing initiation of
ARTat CD4 >500 cells/mm3 to initiation at <350 cells/mm3 [56].
Observational evidence to support the idea that ART reduces HIV transmission among
MSM is mixed. Surveillance data and longitudinal cohort studies suggest that HIV incidence
among MSM has fluctuated, in some cases increasing, in spite of widespread availability of
ART [42–44,57–63]. To estimate how ART has affected HIV transmission among MSM,
some studies have calculated a per-partner or per-act transmission risk and compared these
rates pre and post-HAART [13,64]. For example, the Health in Men Australian cohort
(2001–2007) used behavioral risk data and annual HIV incident infections to estimate per-
contact HIV transmission risk. In Sydney–—with overall stable incidence of HIV and
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increasing uptake of ART–—the authors conclude that the overall per-contact risk of
transmission has not changed in spite of increased ART coverage and more effective
regimens [13].
Other studies have combined HIV surveillance and/or cohort data from communities with
high ART coverage to compare trends in ART use and transmission (Table 1) [43,57,65–
67]. For instance, one older study in San Francisco (1995–1999) using community
surveillance and clinic data concluded that any decrease in HIV infectivity gained by
widespread use of ART may have been offset by increases in condomless anal intercourse
and/or STIs [57]. A more recent San Francisco study using HIV surveillance data (2004–
2008) described a significant correlation between decreased annual mean community viral
load (CVL, an aggregate measure of the total known viral load among a particular
population) and decreases in newly diagnosed cases of HIV; however the association with
HIV incidence measured with the BED assay was not statistically significant [65]. A similar
study using surveillance data (2004–2008) from Washington DC found a decrease in mean
CVL and an increase in the proportion of known HIV-positive persons virally suppressed,
but a statistically significant increase in newly diagnosed cases of HIV [67]. In these data,
MSM had the highest proportion of individuals with undetectable viral load compared with
other risk groups; however, black MSM were less likely to have undetectable viral load
compared to white MSM [67]. A study conducted in Vancouver reported similar
associations between decreases in CVL and new HIV diagnoses [43]; however, the role of
injection drug use in driving these trends is unclear [68,69] and government surveillance
reports show fluctuations in new HIV diagnoses among MSM in British Columbia with no
overall change compared to 2003 [63]. Among Vancouver MSM specifically, HIV
prevalence is steady and slightly rising, likely reflecting increases in survival as well as new
diagnoses [70]. In contrast, a report from Denmark using national HIV surveillance and
clinic data showed that rising proportions of HIV-infected MSM on suppressive treatment
were correlated with stable rates of new HIV diagnoses in spite of increasing proportions of
MSM reporting condomless anal intercourse [66].
Due to their reliance on aggregate data and on new diagnosis reports rather than on new
incident infections, these ecological studies are unable to draw causal inferences about the
individual-level processes driving transmission. Their mixed results suggest that
characteristics of specific geographic epidemics as well as behavioral patterns likely
contribute to the population-level impact of ART on HIV transmission among MSM.
The majority of data available for the impact of ART among MSM are from developed
countries in North America, Western Europe and Australia. As a result, what we know about
ART’s effect on HIV transmission comes from a small subset of MSM, limiting the
generalizability of these results within other social, cultural and epidemic settings. While
recognizing the barriers of stigma, discrimination and legal repercussions, it is clear that
more research is needed in this regard among MSM populations in South America, Africa,
Central Europe and Asia. In order to inform optimal ART recommendations, we also need to
better understand the social and cultural environments in which new sexual behavioral
trends are evolving.
Going forward, there are great opportunities to further our understanding of the individual-
and population-level transmission dynamics of HIV and ART among MSM. For example,
applying the tools of phylogenetic analysis, researchers may be able to identify the most
likely source of an individual’s HIV infection, describe the size and distribution of clusters
of new cases in the population, and assess the relative contributions to new transmissions by
persons at various stages of infection. For example, a phylogenetic transmission cluster
analysis with matched epidemiological and clinical data among MSM in the UK found that
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those who are recently infected, are untreated, and have a concomitant STI may be
contributing disproportionately to secondary transmission [71]. While an individual-level
randomized clinical trial to directly evaluate the efficacy of ART for prevention in MSM
may not be feasible or ethical (Cohen et al., in press CLIN Trials), well-designed
observational studies of seroconcordant and discordant couples–—as reported with
heterosexual subjects [3,4]–—allow researchers to measure both the risk of acquiring as well
as transmitting HIV. Two such studies involving MSM couples are currently enrolling or
planned in Europe and Australia [72,73].
The benefits of TasP for MSM are highly plausible, but not certain. The results of HPTN
052 have generated great urgency for maximizing the prevention benefit of ART. The
impact of ART on HIV transmission via anal intercourse requires further evaluation,
however, given the inconclusive observational data currently available for MSM and the
challenging biological and behavioral risk factors that may be present. If TasP becomes part
of prevention policy for MSM, implementation of early treatment in combination with other
prevention methods including promotion of condom use to prevent other STIs, expanded
STI treatment, structural and behavioral interventions, and earlier diagnosis will be critical.
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Table 1
Ecological studies of ART and new diagnoses of HIV.






















No association was found between trends in
the mean CVL and newly diagnosed HIV/
AIDS cases. MSM had a higher proportion
of virally suppressed cases













Reductions in CVL were significantly
associated with fewer annual HIV
diagnoses, though not with estimated HIV
incidence using the STARHS method



















Any decrease in per contact risk of HIV
transmission due to HAART use appears to
have been countered or overwhelmed by
increases UAI














Rising numbers of individuals receiving
HAART and rising proportions of treated
individuals with VL < 500 copies/mL were
strongly associated with decreased number
of HIV diagnoses per year
















used as proxy for
incidence
Increasing numbers of treated MSM
coincides with stable numbers of newly
notified HIV positive MSM and increasing
STI diagnoses, suggesting reduced
infectiousness among HIV infected MSM
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